Home » Newsletters » BioWorld Science

BioWorld Science

June 9, 2008

View Archived Issues

GDC-0449 shows safety and good PK profile in patients with advanced solid cancers

CuraGen reports results from phase I/II study of CR011-vcMMAE

Preclinical evaluation of novel gene therapy for the treatment of hereditary inclusion-body myositis

JNK inhibition shows benefit in experimental endometriosis

Novartis presents update on pipeline of novel vaccine candidates

First phase I clinical results for JM-1232 reported

TorreyPines initiates phase I clinical trial for oral prodrug of tezampanel

Positive opinion issued to broaden use of Erbitux, including first-line colorectal cancer

Indevus presents update on NDA for Nebido

Achillion nominates ACH-1625 as first clinical candidate in HCV protease program

Nuvelo initiates enrollment in phase Ib trial of bolus plus infusion dosing of NU-172

Nine European countries grant national marketing authorizations to SpePharm's Loramyc

Transcept to submit NDA to FDA for Intermezzo in the third quarter of 2008

Medicago reports positive results from preclinical study in ferrets of H5N1 VLP vaccine

Ipsen to acquire Tercica

FDA approves Angioblast's IND application to initiate phase II trial of allogeneic stem cells

Intercytex completes enrollment in phase III trial of Cyzact in venous leg ulcers

Arana successfully engineers second candidate antibody under collaboration with CSL

Merck Serono and ZymoGenetics initiate phase II/III trial of atacicept in SLE

Epix identifies three lead candidates in third G-protein-coupled receptor discovery program

CHMP recommends refusing Takeda's MAA for ramelteon

PharmaGap's PhG-alpha-1 reduces tumor size, increases survival in colon cancer models

Recent Devgen patent discloses novel agents for glaucoma

Novel antiinflammatory agents disclosed in recent patent literature

Recent Roche patent reports new therapeutic agents for urological disorders

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 1, 2026.
Emerging therapeutic strategies for Parkinson’s at ADPD 2026
BioWorld
Parkinson’s disease (PD) involves the progressive loss of dopaminergic neurons, particularly in the substantia nigra. This neurodegeneration is linked to the...
With improved technologies, biomarkers, failed drugs may come into their own
BioWorld
At BioEurope Spring 2026, pharma representatives and investors shared their thoughts about current and future landscapes of different disease areas, and on how to...
Small-molecule TREM2 agonist advances to treat Alzheimer’s
BioWorld Science
Microglia play a central role in the neuroinflammation associated with Alzheimer’s disease (AD). These cells act as the brain’s immune system and respond to...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 31, 2026